Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HLVXNYSEMKT:IGCNASDAQ:MISTNYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHLVXHilleVax$1.95+2.6%$1.90$1.34▼$15.25$95.27M0.74450,745 shs238,833 shsIGCIGC Pharma$0.31-5.2%$0.31$0.25▼$0.50$24.50M1.48337,456 shs214,616 shsMISTMilestone Pharmaceuticals$1.94+2.6%$1.46$0.63▼$2.75$101.05M0.92942,271 shs615,457 shsZOMZomedica$0.12$0.09▼$0.17$95.35M1.034.51 million shs790,936 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHLVXHilleVax+2.63%+3.72%+4.84%+22.64%-85.09%IGCIGC Pharma+0.98%+2.66%-6.65%+4.39%+30,899,900.00%MISTMilestone Pharmaceuticals+2.65%+12.79%+36.62%+120.45%+44.78%ZOMZomedica0.00%0.00%0.00%0.00%-33.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHLVXHilleVax2.4974 of 5 stars3.03.00.00.00.03.31.3IGCIGC Pharma1.9605 of 5 stars3.50.00.00.02.31.70.0MISTMilestone Pharmaceuticals1.6612 of 5 stars3.23.00.00.00.02.50.0ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHLVXHilleVax 2.00Hold$3.0053.85% UpsideIGCIGC Pharma 3.00Buy$3.881,154.05% UpsideMISTMilestone Pharmaceuticals 2.40Hold$7.00260.82% UpsideZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest IGC, HLVX, MIST, and ZOM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.004/1/2025MISTMilestone PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025MISTMilestone PharmaceuticalsTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/28/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AIGCIGC Pharma$1.24M19.92N/AN/A$0.08 per share3.86MISTMilestone Pharmaceuticals$1M103.71N/AN/A$0.25 per share7.76ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)IGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AMISTMilestone Pharmaceuticals-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest IGC, HLVX, MIST, and ZOM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MISTMilestone Pharmaceuticals-$0.19-$0.31-$0.12-$0.31N/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHLVXHilleVaxN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHLVXHilleVaxN/A25.3225.32IGCIGC Pharma0.021.150.98MISTMilestone Pharmaceuticals4.064.674.67ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHLVXHilleVax86.42%IGCIGC Pharma3.87%MISTMilestone Pharmaceuticals86.18%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipHLVXHilleVax24.90%IGCIGC Pharma31.48%MISTMilestone Pharmaceuticals19.50%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableIGC, HLVX, MIST, and ZOM HeadlinesRecent News About These CompaniesZomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - MorningstarJune 25 at 10:06 PM | morningstar.comMZomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 20, 2025 | finanznachrichten.deTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24, 2025 | click2houston.comCHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comPIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comANYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comAZomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | finanznachrichten.deZomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | accessnewswire.comAZomedica Corp.: Zomedica Launches the TRUFORMA Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | finanznachrichten.deZomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID DiagnosisFebruary 6, 2025 | accessnewswire.comAZomedica Corp (ZOM) Stock Sees Market Value Hit $118.58 million: What Are the Implications?February 4, 2025 | bovnews.comBZomedica Corp (ZOM) Stock Trading RecapJanuary 17, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseDon’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeGameStop Buys Bitcoin: Smart Strategy or Big Mistake?By Thomas Hughes | May 28, 2025View GameStop Buys Bitcoin: Smart Strategy or Big Mistake?IGC, HLVX, MIST, and ZOM Company DescriptionsHilleVax NASDAQ:HLVX$1.95 +0.05 (+2.63%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.51%) As of 06/26/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.IGC Pharma NYSEMKT:IGC$0.31 -0.02 (-5.24%) Closing price 06/26/2025 03:57 PM EasternExtended Trading$0.31 +0.00 (+0.32%) As of 06/26/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Milestone Pharmaceuticals NASDAQ:MIST$1.94 +0.05 (+2.65%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.95 +0.01 (+0.52%) As of 06/26/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
